Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma

Biomedicine and Pharmacotherapy

Volumn 73, Issue , 2015, Pages 123-128

  Zhang, Meng ^a   Fan, Hai Yan ^a   Li, Sheng Chao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

C Myc; Chemosensitivity; Growth; Pancreatic ductal adenocarcinoma

Indexed keywords

10058 F4; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CYCLINE; GEMCITABINE; UNCLASSIFIED DRUG; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; GROWTH INHIBITOR; MYC PROTEIN; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; TUNEL ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937800045     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.05.019     Document Type: Article

References (23)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J. Clin. 2014, 64(1):9-29. 2014.
2. Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 2009, 6(12):699-708.
3. Burris H.A.3rd, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15(6):2403-2413.
4. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 1999, 19(1):1-11.
5. Luscher B., Larsson L.G. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 1999, 18(19):2955-2966.
6. Schleger C., Verbeke C., Hildenbrand R., Zentgraf H., Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod. Pathol. 2002, 15(4):462-469.
7. Gomez-Curet I., Perkins R.S., Bennett R., Feidler K.L., Dunn S.P., Krueger L.J. c-Myc inhibition negatively impacts lymphoma growth. J. Pediatr. Surg. 2006, 41(1):207-211. [discussion 207-211].
8. Huang M.J., Cheng Y.C., Liu C.R., Lin S., Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp. Hematol. 2006, 34(11):1480-1489.
9. Lin C.P., Liu J.D., Chow J.M., Liu C.R., Liu H.E. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anti-cancer drugs 2007, 18(2):161-170.
10. Zhang Q.L., Luo C.L., Wu X.H., Wang C.Y., Xu X., Zhang Y.Y., Liu Q., Shen S.L. HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J. Cell. Biochem. 2011, 112(10):2910-2919.
11. Kim J., Roh M., Abdulkadir S.A. PIM1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 2010, 10:248.
12. Yin X., Giap C., Lazo J.S., Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003, 22(40):6151-6159.
13. Zhou W., Liotta L.A., Petricoin E.F. Cancer metabolism and mass spectrometry-based proteomics. Cancer Lett. 2015, 356(2):176-183.
14. Wang J., Ma X., Jones H.M., Chan L.L., Song F., Zhang W., Bae-Jump V.L., Zhou C. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J. Transl. Med. 2014, 12:226.
15. Son J., Lyssiotis C.A., Ying H., Wang X., Hua S., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496(7443):101-105.
16. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149(3):656-670.
17. Le A., Dang C. Studying Myc's role in metabolism regulation. Methods Mol. Biol. 2013, 1012:213-219.
18. Dang C.V. MYC on the path to cancer. Cell 2012, 149(1):22-35.
19. Guo J., Parise R.A., Joseph E., Egorin M.J., Lazo J.S., Prochownik E.V., Eiseman J. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother. Pharmacol. 2009, 63(4):615-625.
20. Damhofer H., Medema J.P., Veenstra V.L., Badea L., Popescu I., Roelink H., Bijlsma M.F. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. Mol. Oncol. 2013, 7(6):1031-1042.
21. Zhou Y., Tozzi F., Chen J., Fan F., Xia L., Wang J., Gao G., Zhang A., Xia X., Brasher H., et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 2012, 72(1):304-314.
22. Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin. Cancer Res. 2012, 18(20):5546-5553.
23. Biliran H., Banerjee S., Thakur A., Sarkar F.H., Bollig A., Ahmed F., Wu J., Sun Y., Liao J.D. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin. Cancer Res. 2007, 13(9):2811-2821.